Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$113.69 USD
-1.29 (-1.12%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 21 - 40 ( 520 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
AACR 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
And Still the Undisputed Heavyweight Champion of ISM/SM, Ayvakit
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
As Ayvakits? Ascent Across SM Continues-We Preview What''s Next; Reit Buy and Raising Our PT to $125 from $85
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
NNARR Below Buyside Expects; ARR Guided Down; Is FY25E Guide at Risk?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department